Catalyst Pharmaceutical Partners (NASDAQ: CPRX) stock found a bottom after sell-off (tax-losses) in the mid-December 2012 and now offers a solid trading opportunity. Besides technical analysis, there are more reasons to join this trade: CPRX announced on December 27th that it received a Nasdaq Staff Deficiency Letter for not compliance with the Minimum Bid Price requirement ($1/share) […]
Shipping Industry was one of the hottest stock market segments today. Some of the market analysts believe that the spike in share prices is a response to the Baltic Dry Index (BDI), which is going into a positive territory since been trampled at the 2012. Anyhow, looks like bottom has been formed in the one […]
Amicus Therapeutics (FOLD) has been profiled as a bounce play from December 31th, 2012. Since then FOLD shares gained over 50% (as of now) and have continued their march to the new highs. Today Amicus Therapeutics announced positive preliminary results from all 4 dose cohorts in a Phase 2 study (Study 010) to evaluate the […]
Aeterna Zentaris Inc. (AEZS) On December 28th Aeterna Zentaris announced that it has reached an agreement with the U.S. Food and Drug Administration (“FDA”) on a Special Protocol Assessment (“SPA”) for an upcoming Phase 3 registration trial in endometrial cancer with its doxorubicin peptide conjugate, AEZS-108. Optimistic market reaction on this announcement boosted AEZS shares […]
Magnum Hunter Resources Corporation (NYSE: MHR) today announced production results from its two new Eagle Ford Shale wells that have been on production since December 22, 2012. Mr. Gary C. Evans, Chairman and Chief Executive Officer of Magnum Hunter Resources Corporation, noted: These two new Eagle Ford wells are by far our best producers since […]
Cellceutix Corporation stock (CTIX) had impressive run from low 80 cents to over $2.40 in a month+. CTIX stock is in overbought condition (that’s obvious) but most important that it is heavily overvalued. Take a brief look at company’s products and its financials: 1. Cellceutix’s psoriasis compound, Prurisol™ Prurisol is a small molecule, acting on […]
CAMAC Energy Inc. (NYSE CAK) today announced that the Company’s Chairman and CEO, Dr. Kase Lawal, has adopted a prearranged trading plan in accordance with guidelines specified by Rule 10b5-1. Dr. Lawal will purchase up to 2 million shares of the Company’s common stock from time to time on the open market starting from November […]
Tranzyme, Inc. (TZYM) announced today that its drug candidate, TZP-102, did not meet its primary efficacy endpoint. Tranzyme’s Phase IIb study was for two doses of TZP-102 taken once daily against a placebo. Even all patients saw a reduction in gastroparesis symptoms after 12 weeks of treatment, the difference between TZP-102 and placebo was minimum […]
MRI Interventions (MRIC), a company with a revolutionary ClearPoint system that enables neurosurgeons to see inside the brain in real-time using direct MRI guidance while performing minimally invasive surgical procedures, today released strong 2012 third quarter (Q3) financial results. To-date, MRI Interventions has successfully implemented its ClearPoint system in 18 sites with the first case […]
Guided Therapeutics, Inc. (GTHP) today announced that it has submitted to FDA its PMA (premarket approval amendment) for the LuViva Advanced Cervical Scan (a non-invasive device used to detect cervical disease that leads to cancer). LuViva has been under FDA PMA review since September 23, 2010. FDA declined LuViva in January 20, 2012. In July, […]
